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AbstrAct
A rising number of non- tuberculous mycobacterial (NTM) 
isolates are being identified in UK clinical practice. 
There are many uncertainties around the management 
of non- tuberculous mycobacterial pulmonary disease 
(NTM- PD), including its epidemiology, diagnosis, 
treatment and prevention. Regional variations in how 
patients with NTM- PD are managed reflects the lack of 
standardised pathways in the UK. Service optimisation and 
multidisciplinary working can improve the quality of care 
for patients with NTM- PD, including (1) better identification 
of patients at risk of NTM- PD and modification of risk 
factors where applicable; (2) standardisation of reference 
laboratory testing to offer clinicians access to accurate and 
prompt information on NTM species and drug sensitivities; 
(3) development of recognised specialist NTM nursing 
care; (4) standardisation of NTM- PD imaging strategies 
for monitoring of treatment and disease progression; (5) 
establishment of a hub- and- spoke model of care, including 
clear referral and management pathways, dedicated 
NTM- PD multidisciplinary teams, and long- term patient 
follow- up; (6) formation of clinical networks to link experts 
who manage diseases associated with NTM; (7) enabling 
patients to access relevant support groups that can 
provide information and support for their condition; and 
(8) development of NTM research groups to allow patient 
participation in clinical trials and to facilitate professional 
education.
IntroductIon
Between 1995 and 2012, the incidence of 
non- tuberculous mycobacterial (NTM) 
culture positive isolates increased eightfold in 
England, Wales and Northern Ireland from 
0.9 per 100 000 population in 1995 to 7.6 per 
100 000 in 2012. This incidence is now similar 
to that of tuberculosis (TB), cases of which 
are now declining.1–3 Around 200 species of 
Mycobacteria have been identified over a spec-
trum of pathogenicity, although most do not 
cause disease in humans.4–6 While the rise in 
incidence may be driven by factors such as 
improved awareness and better diagnostic 
tools, it is likely to be a true representation 
of the increased frequency with which these 
robust environmental organisms are now 
isolated.
The majority of clinical NTM cases manifest 
as pulmonary disease (non- tuberculous myco-
bacterial pulmonary disease (NTM- PD)), with 
a smaller number affecting extrapulmonary 
sites such as the skin and soft tissue.7 8 Myco-
bacterium avium complex (MAC, including 
M. avium, M. intracellulare and M. chimaera), 
and M. abscessus are associated with around 
90% of the total number of reported cases of 
NTM- PD.9–11
Uncertainties around the management 
of NTM- PD include its epidemiology, diag-
nosis, treatment and prevention. These are 
addressed to some extent in the 2017 British 
Thoracic Society (BTS) guidelines12; however, 
variations in care remain for UK patients with 
NTM- PD. Paediatric NTM- PD is rare outside 
of the cystic fibrosis (CF) population, and 
hence the evidence base on which to guide 
management decisions is even smaller than 
for adult NTM- PD.13 An in- depth discussion 
of paediatric NTM- PD is beyond the scope 
of this article, although we recommend that 
such cases are managed in consultation with 
specialist centres. Using a clinical case of 
NTM- PD, we will review the current status 
and challenges of patient management and 
consider practical ways in which NTM services 
may be optimised in the future. While the 
focus of this article is the UK, many issues 
are relevant to the global management of 
NTM- PD.
Case: A 67- year- old slim- build woman with a 
history of smoking- associated chronic obstructive 
pulmonary disease (COPD) presents to her commu-
nity COPD clinic with a productive cough and 
unintentional weight loss. Her COPD is managed 
with inhaled corticosteroids in combination with 
long- acting bronchodilators, and she has recently 
experienced recurrent respiratory infections, despite 
repeated courses of antibiotics. She also has ongoing 
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box 1 Factors which increase the risk of developing non- tuberculous mycobacterial pulmonary disease12–21
 ► Alcohol misuse
 ► Biological agents
 ► Chronic kidney disease
 ► Diabetes
 ► Female gender
 ► Gastro- oesophageal reflux disease
 ► Immunocompromise, primary or secondary to disease or drug therapies
 ► Inhaled corticosteroids
 ► Low body mass index
 ► Pneumoconiosis
 ► Underlying structural lung disease, for example, bronchiectasis, and COPD (chronic obstructive pulmonary disease)
gastro- oesophageal reflux disease (GORD). Chest X- rays carried 
out by the COPD team look generally similar to previous imaging, 
though occasional nodularity that appeared to resolve on repeat 
imaging was noted.
rIsk fActors
Various factors can increase the risk of developing NTM- 
PD; these are outlined in box 1 and discussed in more 
detail as follows. Immunocompromise is a major risk 
factor for NTM- PD, whether it is caused by the use of 
immunosuppressive drugs, by a systemic illness such as 
rheumatoid arthritis (RA), HIV or malignancy, or by a 
primary immunodeficiency.12 14 15 The use of biological 
agents, such as antitumour necrosis factor drugs, to treat 
RA and other autoimmune diseases has also been shown 
to increase the risk of NTM infection.16
NTM also causes pulmonary infections in apparently 
immunocompetent hosts, and those with underlying 
structural lung damage are at greatest risk.17 There is 
a high prevalence of NTM- PD in patients with CF and 
bronchiectasis.15 18 19 As in the case described, COPD is 
also a common predisposing condition for NTM- PD, 
with the risk increased further when patients are using 
inhaled corticosteroids, particularly at high doses.20 21
Other risks for NTM- PD in immunocompetent patients 
include host factors such as low body mass index (BMI), 
female gender and vitamin D deficiency, and the pres-
ence of comorbidities such as GORD, diabetes and 
chronic kidney disease.14 15 Some of these factors are 
modifiable and, where possible, clinicians and patients 
should address them to reduce NTM infection risk.14
We recommend that appropriate assessments are 
performed, although their extent depends on the 
patient’s clinical features plus available local resource. An 
initial screen should be carried out on all adult patients 
diagnosed with NTM- PD, comprising a thorough review 
of medication history, assessment for underlying disease 
leading to immunocompromise and HIV testing.
As bronchiectasis is commonly associated with NTM- 
PD, we suggest testing immunoglobulins in all patients 
with bronchiectasis to exclude an immunological basis 
for the structural lung disease. Other conditions, such as 
CF and alpha 1 antitrypsin deficiency, should be excluded 
in line with local policies. The presence of significant 
bronchiectasis or a characteristic pattern of microbial 
isolation could suggest underlying CF, which should be 
excluded.
If these tests do not identify any specific risk factors, we 
recommend discussing the case with immunologists or 
clinicians with expertise in immunodeficiency to deter-
mine whether further assessment is required.
PresentAtIon
Like our case, patients with an underlying aetiology, such 
as COPD or bronchiectasis, may present with respiratory 
symptoms and may be seen in a specialist service. This 
provides an opportunity for NTM infection to be recog-
nised by respiratory teams and the patient referred for 
diagnostic tests. Patients with no underlying aetiology 
usually present with symptoms to primary care. The possi-
bility of NTM infection may not be recognised initially, 
resulting in a potential diagnostic delay. If patients are 
referred to secondary care, they may be seen in a general 
respiratory clinic with little experience of diagnosing and 
managing NTM- PD.
There is an urgent requirement for clear referral path-
ways for NTM- PD, both from primary to secondary care 
and from secondary care to NTM specialists. In addition, 
education will highlight the diverse presentations of 
NTM- PD to all relevant healthcare providers.
Case: Our patient has risk factors for the development of 
NTM- PD, including low BMI due to weight loss and slim build, 
structural lung disease, GORD and inhaled corticosteroids. She 
has presented with respiratory symptoms to her COPD clinic so 
she is referred for diagnostic tests.
dIAgnosIs of ntM-Pd
Microbiological
UK and US guidelines provide microbiological diag-
nostic criteria for NTM- PD. Unlike TB, a patient must 
have two or more positive sputum samples, or one posi-
tive bronchial wash/lavage or compatible histopatholog-
ical findings with one positive culture of the same NTM 
species.12 22
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Table 1 Recommended microbiological tests to support a diagnosis of NTM- PD
Test Sensitivity Specificity Cost Availability Comment
Tests to detect NTM in respiratory samples12 22
Microscopy (AFB smear) Low Moderate Low High Rapid, but variable sensitivity 
and cannot distinguish 
NTM from Mycobacterium 
tuberculosis
Direct molecular detection 
on primary sample
Moderate High Moderate Low NTM- specific: costly and less 
sensitive than conventional AFB 
culture. Limited uptake: TB PCR 
is useful as a rule- out test for 
NTM on smear- positive samples
Mycobacterial culture High High Low High Most sensitive method to detect 
NTM from respiratory samples.
Optimal results require the use 
of both solid and liquid media. 
Slow results, taking days to 
weeks
Tests to speciate and type NTM in respiratory samples12 22
1. Line probe assays
2. PCR product restriction 
analysis
3. Partial gene sequencing
4. MALDI- TOF
Moderate High Moderate/high Low/moderate Enables species identification, 
including subspecies of 
M. abscessus. May require 
phenotypical drug sensitivity 
testing to determine inducible 
macrolide resistance
WGS High High Moderate/high Low/moderate Improved discrimination of 
strains enables WGS to be used 
to investigate possible person- 
to- person transmission events
AFB, acid- fast bacilli; MALDI- TOF, matrix- assisted laser desorption ionisation- time of flight ; NTM, non- tuberculous mycobacteria; NTM- PD, 
non- tuberculous mycobacterial pulmonary disease; PCR, polymerase chain reaction; TB, tuberculosis; WGS, whole- genome sequencing.
To establish the diagnosis of NTM- PD, the collection of 
three good- quality sputum specimens on different days 
is preferred. Potential causes of pulmonary disease must 
also be excluded, such as other bacteria or fungi.12 22
Accurate mycobacterial speciation enables clinicians 
and scientists to determine its potential clinical signifi-
cance, identify available antimicrobial options, record 
epidemiology and characterise new species. All NTM 
isolates from respiratory samples should be identified to 
at least species level using validated molecular or mass 
spectrometry techniques.12 Suggested microbiological 
tests are outlined in table 1.12 22
There is regional variation in the microbiological 
diagnosis of NTM- PD in the UK, and patients may have 
different tests depending on their route of referral and 
which laboratory performs the tests. This makes it diffi-
cult to compare national data, although the National 
Reference Laboratories in the UK are currently under-
taking whole- genome sequencing on all positive myco-
bacterial cultures received.
This lack of standardisation of diagnostic testing is a 
significant barrier to a timely diagnosis of NTM- PD, 
which in turn delays treatment, if required. In addition, 
the increased incidence of NTM culture- positive isolates 
has placed additional pressure on laboratories and will 
do so for the foreseeable future unless an appropriate 
solution is found.
clinical
UK guidelines also provide criteria for a clinical diag-
nosis of NTM- PD. This requires the presence of respira-
tory symptoms alongside appropriate radiology, plus the 
exclusion of other diagnoses.12
It can be difficult to distinguish clinically meaningful 
NTM- PD from NTM colonisation, which is indicative of 
a patient with previously damaged lungs and impaired 
local host defences and no evidence of ongoing NTM- 
driven disease.
radiological
Radiology is a key component in the diagnosis and 
follow- up of NTM- PD. All patients with suspected NTM- PD 
should have computerised tomography (CT) imaging of 
the thorax, as the chest X- ray is often normal or non- 
specific.12 Examples of imaging seen with NTM infec-
tion are shown in figure 1. Systems for scoring NTM- PD 
radiology have been developed but are not widely used 
outside of research studies or specialist centres.23–25
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Figure 1 Radiological imaging features typical of NTM lung infection. (A) Fibrocavitatory NTM- PD in a patient who has 
M. kansasii. Axial CT image shows a cavity in the apex of the left upper lobe with adjacent satellite nodules. (B) Nodular–
bronchiectatic NTM- PD. CT image from a 75- year- old female patient with MAC. Axial CT image at the carina shows 
bronchiectasis and bronchial wall thickening in the posterior segment of the right upper lobe (arrow) with additional scattered 
areas of peripheral bronchiectasis, mucus plugging and centrilobular nodularity in the left upper (arrowhead) and lower lobes. 
(C) Nodular–bronchiectatic NTM- PD in a patient with variant cystic fibrosis who has grown MAC and M. abscessus. Axial CT 
image just below the carina shows widespread bronchiectasis and bronchial wall thickening with centrilobular nodules in the 
right lower lobe. Peripheral mucus plugging is a more common finding in NTM- PD and air bubbles or lucency is often seen 
within the mucus (arrow). There is an ancillary finding of air trapping causing lucent areas of lung. (D) Nodular–bronchiectatic 
NTM- PD in a patient who has MAC. There is more severe bronchiectasis in the middle lobe, which is cystic and varicose 
in appearance (circle). There are ancillary findings of chest wall deformity with volume loss in the right hemithorax and little 
chest wall body fat. Reproduced by the kind permission of Dr Joanne Cleverley and Dr Besma Musaddaq of the Department 
of Radiology, Royal Free Hospital, London, UK. CT, computerised tomography; MAC, Mycobacterium avium complex; NTM, 
non- tuberculous mycobacteria; NTM- PD, non- tuberculous mycobacterial pulmonary disease.
Case: Our patient underwent a CT scan and sputum samples 
were collected for analysis. The CT scan showed underlying 
emphysema with inflammatory changes in the middle lobe, 
lingular bronchiectasis and non- cavitating nodularity in 
both lungs. Sputum microbiology was smear- negative for AFB; 
however, two cultures grew mycobacterial species after 2 weeks. 
This was subsequently confirmed as M. avium. The COPD team 
want to know whether or not she should be treated for this and 
should contact their local specialist, with an interest in respira-
tory infection, to discuss the management of her condition.
MAnAgeMent
There are regional variations in how patients with 
NTM- PD are managed after their diagnosis, reflecting the 
lack of standardised pathways in the UK. A diagnosis does 
not necessarily translate into an immediate treatment 
requirement for the NTM, especially in patients with mild 
symptoms and/or an absence of radiological findings, 
but long- term follow- up is strongly advised. Currently, 
there is limited evidence and no clear consensus on when 
to start treatment, with the exception of severe disease, 
for example, the fibrocavitary phenotype of MAC.22 If 
treatment is deemed necessary, the regimen depends on 
the infecting NTM species and in some cases requires a 
combination of oral and intravenous or inhaled medica-
tions. In certain clinical scenarios, such as a symptomatic 
patient with M. abscessus infection and severe under-
lying lung disease, treatment is likely to be undertaken 
to control disease progression and to improve patient 
quality of life.
In addition, NTM have high levels of intrinsic resis-
tance. While for some antibiotics, such as macrolides, in 
vitro drug susceptibility testing (DST) is associated with 
clinical efficacy, there is a generally inconsistent relation-
ship between DST and clinical disease response.19 This 
makes the choice of antibiotics for NTM less straight-
forward than for most cases of TB. In addition, many 
pathogenic NTM species are slow- growing, leading to 
 o
n
 June 29, 2020 at BVA. Protected by copyright.
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2020-000591 on 21 June 2020. Downloaded from 
Lipman M, et al. BMJ Open Resp Res 2020;7:e000591. doi:10.1136/bmjresp-2020-000591 5
Open access
Table 2 Factors influencing the decision to initiate therapy for NTM- PD
Host factors Mycobacterial factors Environmental factors
Severity of respiratory and 
constitutional symptoms (eg, cough, 
sputum production, breathlessness, 
fatigue and malaise)
Virulence/pathogenicity (usually identified from 
mycobacterial speciation)
Promotion of NTM persistence (eg, 
through the use of inhaled steroids)
Comorbidities Drug resistance profile (note: there is usually 
only limited information available)
Ongoing exposure to mycobacteria
Degree of lung damage (severity and/
or extent of disease)
    
NTM, non- tuberculous mycobacteria; NTM- PD, non- tuberculous mycobacterial pulmonary disease.
long treatment durations.26 Intolerance of therapies is 
common and options can be limited by drug–drug inter-
actions and the patient’s comorbidities.26
Therefore, the decision to initiate treatment is complex 
and should consider the factors outlined in table 2.
The surgical management of NTM- PD has been shown 
to result in favourable patient outcomes in specific cases.27 
This requires multidisciplinary assessment and expert 
surgical input in a centre experienced in managing indi-
viduals with NTM- PD, alongside the careful selection of 
appropriate patients, such as those with focal lung disease. 
Patients should commence antibiotic treatment prior to 
surgery, which should be continued for 12 months after 
culture conversion.12
The complexities and chronicity of care argue for the 
development of an NTM specialist nurse role. Currently, 
most services rely on ad hoc support from TB, infectious 
disease, respiratory, COPD and bronchiectasis nurses; 
or have no specialist nurse input at all. The resulting 
regional variation in standards of care and competencies 
will not be resolved until a clear career pathway into NTM 
nursing is established. In the short term, local teams are 
best placed to drive service improvement by identifying 
and using available resource. For example, in some 
areas, TB nurses may be able to provide care via a case- 
management model similar to the established nursing 
pathway used for patients with TB.28 Elsewhere, it may 
be more appropriate for specialist nursing groups to take 
this on. Communication, education and shared examples 
of good practice between different nursing teams enable 
regional variation to be minimised over time.
Ongoing patient monitoring depends on available 
resource, as well as the patient’s specific management 
plan and needs. In general, we recommend that support 
is available on an ongoing basis, for example, via tele-
phone contact with an NTM specialist nurse, while face- 
to- face clinical review occurs every 6 weeks to 6 months 
depending on need. Serial sputum cultures can be 
performed outside these assessments, although in prac-
tice, it is often easier for patients to provide samples at 
clinic visits.
Airway clearance, including physiotherapy, is a key 
component of NTM- PD care, which can counteract respi-
ratory decline. Unfortunately, outside of specialist NTM 
centres, there are huge variations in the accessibility and 
responsiveness of physiotherapy services for patients with 
NTM.
We believe quality of life for patients with NTM- PD is a 
key consideration within any care plan. This may include 
an ongoing dialogue regarding the emergence and 
management of treatment- related side effects, and an 
assessment of social support needs, such as transport to 
appointments. Psychological interventions are also rele-
vant for patients who live with a chronic illness that can 
seem mysterious, poorly understood and hard to explain 
to others.29 Nutritional status is important, given that it 
can be impaired by the disease itself, drug treatment and 
associated low mood. NTM- PD outcomes are worse in 
patients who are losing weight and poorly nourished.
A multidisciplinary team (MDT) management 
approach is recommended to ensure access to all special-
ties required to manage patients with NTM- PD.
ntM Mdt coMPosItIon
Other areas of lung disease, such as CF, bronchiectasis 
and TB, already have established and successful MDTs. 
Experience gained in these areas can be used as an excel-
lent starting point for the development of NTM MDTs; 
the role of each specialist is considered in more detail as 
follows.
respiratory physician
The respiratory physician is responsible for optimising a 
patient’s underlying disease and associated risk factors, 
plus providing ongoing monitoring.
It is imperative that the physician discusses treatment 
options with the patient before a decision is made, and 
the views of the patient are sought on the potential risks 
and benefits of starting treatment. This is emphasised in 
the 2017 BTS guidelines.12
Case: The Reference Laboratory reports that the M. avium 
isolated from our patient was phenotypically sensitive to macro-
lides. Following discussion of treatment options, the patient opts 
to start azithromycin, rifampicin and ethambutol. In an attempt 
to protect her lungs from further damage, a proton pump inhib-
itor is initiated to improve her GORD and her dose of inhaled 
corticosteroids is reduced. She is monitored for improvement, as 
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well as possible worsening in her breathing following the reduc-
tion in inhaled corticosteroids.
specialist pharmacist
The pharmacist has an important role in ensuring good 
patient outcomes in patients who often have comorbidi-
ties and are on complex long- term drug regimens. The 
pharmacist can provide advice on avoiding potential 
drug–drug interactions. For example, the case describes 
rifampicin, a potent inducer of certain cytochrome P450 
enzymes, which can accelerate metabolism of multiple 
drugs, including corticosteroids. Pharmacists can help 
manage adverse events, for example, through patient 
education, the introduction of new medicines and thera-
peutic drug monitoring.
specialist nurse
Nurses have knowledge of drugs, their side effects and 
interactions, have developed strategies to assist with 
management, and can provide support and advice, espe-
cially as a point of contact should any urgent issues arise. 
They also have a key role in risk assessment and adher-
ence support through regular nurse- led follow- up.
specialist physiotherapist
The main aim of the physiotherapist is to enhance the 
patient’s participation in everyday life, through assess-
ment, advice, education and physical intervention. 
They have a key role in mobilising respiratory secretions 
through chest physiotherapy, reducing breathlessness 
and maintaining or improving exercise tolerance.
radiologist
The radiologist has a vital role in the diagnosis and 
management of NTM- PD, and we advocate close working 
between the clinical and radiological teams to ensure 
that patients achieve the best possible outcomes.
Radiologists can provide diagnostic support, particu-
larly where NTM- PD is not suspected, by recognising the 
CT imaging features of fibrocavitary and/or nodular–
bronchiectatic NTM- PD, and advising the physician on 
target sites within the lungs or mediastinum for broncho-
scopic lavage or biopsy to confirm a diagnosis. Serial CT 
imaging is also important for monitoring disease progres-
sion and response to treatment.
Case: Once established on treatment, our patient’s condition 
steadily improved. While she remained breathless on exertion, the 
number of exacerbations reduced and she was able to gain weight. 
Her sputum cultures for AFB became negative at 3 months and a 
follow- up CT scan at 6 months showed resolution of her nodules. 
She is scheduled to receive 12 months of treatment from when she 
became sputum culture negative.
InfectIon control
In general, NTM are not considered to be transmissible 
between patients.30 However, since 2012, there have been 
several concerning reports in CF centres of person- to- 
person transmission of M. abscessus. This is likely to be 
through fomite spread or the generation of long- lived 
infectious aerosols.30–32 In the setting of CF, particularly, 
it seems prudent that rigorous infection control meas-
ures are in place.
Another example of the importance of infection 
control is the 2013 outbreak of over 100 cases of life- 
threatening M. chimaera prosthetic valve endocarditis 
and disseminated disease in people with previous cardiac 
surgery. This was linked to contaminated heater–cooler 
units used during the patient’s surgery, with the factory 
manufacturing the units being the likely source. Surveil-
lance and heightened clinician awareness are key to 
detect early transmission of NTM.33
Models of cAre
A lack of commissioned NTM services in the UK affects 
all aspects of care for patients with NTM- PD. A model of 
care is required that contains pathways providing seam-
less assessment, investigation and management across a 
number of disciplines and services in line with patients’ 
clinical presentation and need. This must include access 
to new and future high- cost treatments.
An attractive potential model is the commissioning of 
specialist centres that can advise and support other NTM 
services within their geographical region, similar to that 
used by the multidrug- resistant TB network.34 To support 
such a hub- and- spoke model of care, we recommend 
that local clinical networks are set up that link experts 
managing diseases associated with NTM, such as large CF 
units, TB clinics and bronchiectasis teams. This model 
should also include regular regional MDT meetings with 
a dedicated microbiologist and radiologist, where infor-
mation can be shared in real time and local guidelines 
can be developed as required. Non- complex cases of 
NTM- PD could be managed within the disease- specific 
clinical team using an agreed NTM care plan.
PAtIent suPPort
Currently, there is a distinct lack of support for patients 
diagnosed with NTM- PD in the UK. Many are unable to 
source accurate information on their condition outside 
of busy clinic appointments, and are left feeling isolated. 
In response to this unmet need, NTM Patient Care UK 
was founded by patients with NTM and clinicians in 2018. 
Its key aims are to provide education and information 
to increase understanding of NTM for both patients 
and clinicians, and to develop and implement a support 
network for NTM patient communities.
reseArch
We believe that research into NTM- PD can be strength-
ened in the UK in line with the findings of the recent 
US National Institute of Allergy and Infectious Diseases 
report.35 This will enable better understanding of who is 
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at risk of NTM- PD, their clinical pathway and the natural 
history of NTM infection; this, in turn, will support the 
development of drugs that are more effective in treating 
the disease. There are several NTM research groups 
currently established in the UK, including NTM Network 
UK, the European Bronchiectasis Registry (EMBARC) 
and NTM- NET. NTM Network UK is an alliance of clini-
cians, public health scientists and research scientists and 
provides a framework within which NTM infections and 
disease can be systematically investigated, researched 
and managed. EMBARC launched the European NTM 
Registry in 2019 and aimsto gather key epidemiological 
data about the spectrum of patients with NTM- PD to stim-
ulate greater research and interest in the field of NTM- 
PD. NTM- NET is an international network promoting 
clinical research in the field of NTM disease by sharing 
and developing ideas and research protocols. Increased 
collaboration and sharing of data will, we believe, ulti-
mately contribute to improved patient management and 
outcomes for people living with NTM- PD.
conclusIons
Service optimisation and multidisciplinary working can 
improve the quality of care for patients with NTM- PD. 
The following strategies are key to achieve this goal:
 ► Better identification of patients at risk of NTM- PD 
and modification of risk factors where applicable.
 ► Standardisation of reference laboratory testing to 
offer clinicians access to accurate and prompt infor-
mation on NTM species and drug sensitivities.
 ► Development of recognised specialist NTM nursing 
care.
 ► Standardisation of NTM- PD imaging strategies for 
monitoring of treatment and disease progression.
 ► Establishment of a hub- and- spoke model of care to 
include clear referral and management pathways, 
dedicated NTM- PD MDTs to provide access to regional 
NTM experts and long- term patient follow- up.
 ► Formation of clinical networks to bring together clini-
cians involved in the management of diseases associ-
ated with NTM, such as bronchiectasis and COPD.
 ► Enabling patients to access relevant support groups 
that can provide information and support for their 
condition.
 ► Development of NTM research groups to allow 
patient participation in clinical trials and to facilitate 
professional education.
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